Literature DB >> 16474913

Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children.

François X Coudé1, Claire Mignot, Stanislas Lyonnet, Arnold Munnich.   

Abstract

Neurofibromatosis type-1 (NF1) is a common genetic disorder associated with a variety of medical complications, cognitive impairments, and behavioral problems. One hundred and sixteen patients with NF1 (62 males, 54 females; mean age 12.4 years) and 80 typically developing children of the same ages (46 males, 34 females; mean age 11.5 years) were studied in terms of complications and learning impairment (one or more grade repetitions or school exclusion). Seventy of 116 patients had significant learning impairment. Classical complications were present in 53 patients including the three.

Entities:  

Mesh:

Year:  2006        PMID: 16474913     DOI: 10.1007/s10519-005-9040-9

Source DB:  PubMed          Journal:  Behav Genet        ISSN: 0001-8244            Impact factor:   2.805


  11 in total

1.  Teaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches.

Authors:  Laura A Barquero; Angela M Sefcik; Laurie E Cutting; Sheryl L Rimrodt
Journal:  Dev Med Child Neurol       Date:  2015-04-22       Impact factor: 5.449

2.  Educational delay and attainment in persons with neurofibromatosis 1 in Denmark.

Authors:  Karoline Doser; Line Kenborg; Elisabeth Wreford Andersen; Pernille Envold Bidstrup; Anja Kroyer; Hanne Hove; John Østergaard; Sven Asger Sørensen; Christoffer Johansen; John Mulvihill; Jeanette Falck Winther; Susanne Oksbjerg Dalton
Journal:  Eur J Hum Genet       Date:  2019-02-28       Impact factor: 4.246

3.  Functional Connectivity Changes and Executive and Social Problems in Neurofibromatosis Type I.

Authors:  Marisa Loitfelder; Stephan C J Huijbregts; Ilya Milos Veer; Hanna S Swaab; Mark A Van Buchem; Reinhold Schmidt; Serge A Rombouts
Journal:  Brain Connect       Date:  2015-03-31

4.  Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.

Authors:  Jacquelyn A Brown; Ryan J Emnett; Crystal R White; Carla M Yuede; Sara B Conyers; Karen L O'Malley; David F Wozniak; David H Gutmann
Journal:  Hum Mol Genet       Date:  2010-09-07       Impact factor: 6.150

5.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

Review 6.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

7.  Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

Authors:  Kelly A Diggs-Andrews; Jacquelyn A Brown; Scott M Gianino; Joshua B Rubin; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2014-02-06       Impact factor: 10.422

8.  Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1?

Authors:  Stephan C J Huijbregts; Leo M J de Sonneville
Journal:  Behav Genet       Date:  2010-12-24       Impact factor: 2.805

9.  Sporadic and Familial Variants in NF1: An Explanation of the Wide Variability in Neurocognitive Phenotype?

Authors:  Maëlle Biotteau; Sébastien Déjean; Sandrine Lelong; Stéphanie Iannuzzi; Nathalie Faure-Marie; Pierre Castelnau; François Rivier; Valérie Lauwers-Cancès; Eloïse Baudou; Yves Chaix
Journal:  Front Neurol       Date:  2020-05-05       Impact factor: 4.003

Review 10.  The Neurofibromatoses.

Authors:  Said Farschtschi; Victor-Felix Mautner; Anna Cecilia Lawson McLean; Alexander Schulz; Reinhard E Friedrich; Steffen K Rosahl
Journal:  Dtsch Arztebl Int       Date:  2020-05-15       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.